NCT02939755

Brief Summary

To test the efficacy of a web-based stepped collaborative care intervention to reduce symptoms of depression, pain, and fatigue and improve health-related quality of life (HRQL) in advanced cancer patients and to reduce stress and depression, and fewer CVD risk factors in caregivers.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
459

participants targeted

Target at P75+ for not_applicable cancer

Timeline
Completed

Started Dec 2016

Longer than P75 for not_applicable cancer

Geographic Reach
1 country

7 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 14, 2016

Completed
6 days until next milestone

First Posted

Study publicly available on registry

October 20, 2016

Completed
1 month until next milestone

Study Start

First participant enrolled

December 1, 2016

Completed
6.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 1, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2023

Completed
Last Updated

December 16, 2024

Status Verified

December 1, 2024

Enrollment Period

6.6 years

First QC Date

October 14, 2016

Last Update Submit

December 11, 2024

Conditions

Keywords

Collaborative care interventionCancerDepressionPalliative careQuality of lifeFatiguePain

Outcome Measures

Primary Outcomes (1)

  • Quality of life (QoL)

    Functional Assessment of Cancer Therapy - General (FACT-G) questionnaire

    change from baseline at 6 and 12 months

Secondary Outcomes (17)

  • serum Interleukin (IL)-6,(mg/L)

    change from baseline at 6 months and 12 months

  • serum Cancer Antigen 19-9 (u/ml)

    change from baseline at 6 months and 12 months

  • serum carcinoembryonic antigen (u/ml)

    change from baseline at 6 months and 12 months

  • serum Alpha feta protein (u/ml)

    change from baseline at 6 months and 12 months

  • Caregivers' stress

    change from baseline at 6 and 12 months

  • +12 more secondary outcomes

Other Outcomes (2)

  • Health care utilization

    1 year

  • Health care costs

    12 months

Study Arms (2)

Stepped collaborative care intervention

EXPERIMENTAL

The 'Stepped Collaborative Care Intervention' includes at least biweekly contact from a care coordinator by phone and face to face visits occurring approximately every 2 months, and 24 hour 7 day a week access to a website that was specifically designed during the pilot study for advanced cancer patients from socioeconomically disadvantaged backgrounds.

Behavioral: Stepped collaborative care intervention

Enhanced Usual Care

ACTIVE COMPARATOR

Patients randomized to the 'Enhanced Usual Care' arm receive their usual care from their medical team. However, if the patient scores in the clinical range on one or more of the three symptoms s/he will receive education about the symptom and be referred to the appropriate health care provider for further treatment in their community. The care coordinator will follow up with the patient after 3 weeks to assess barriers to treatment and assist further with accessing treatment if needed.

Behavioral: Enhanced Usual Care

Interventions

Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional

Also known as: treatment
Stepped collaborative care intervention

usual care from health providers

Also known as: control
Enhanced Usual Care

Eligibility Criteria

Age21 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients:
  • biopsy and/or radiograph proven diagnosis of hepatocellular carcinoma,cholangiocarcinoma, gallbladder carcinoma or breast, ovarian, or colorectal cancer with liver metastases with a life expectancy of at least one year;
  • age \>21 years;
  • no evidence of thought disorder, delusions, or active suicidal ideation is observed or reported.
  • Caregivers:
  • a spouse or cohabitating intimate partner of an advanced cancer patient being evaluated at the UPMC's Liver Cancer Center and
  • age \>21 years

You may not qualify if:

  • Patients:
  • age \< 21 years,
  • lack of fluency in English,
  • evidence of thought disorder, delusions, hallucinations, or suicidal ideation.
  • Caregivers:
  • lack of fluency in English; and
  • evidence of thought disorder, delusions, hallucinations, or suicidal ideation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (7)

UPMC East

Monroeville, Pennsylvania, 15146, United States

Location

The University of Pittsburgh's Medical Center Passavant Hospital

Pittsburgh, Pennsylvania, 15213, United States

Location

University of Pittsburgh Medical Center Mercy

Pittsburgh, Pennsylvania, 15213, United States

Location

University of Pittsburgh's Medical Center Montefiore Hospital

Pittsburgh, Pennsylvania, 15213, United States

Location

UPMC Presbyterian

Pittsburgh, Pennsylvania, 15213, United States

Location

UPMC St. Margaret

Pittsburgh, Pennsylvania, 15215, United States

Location

UPMC Horizen

Pittsburgh, Pennsylvania, 15219, United States

Location

Related Publications (4)

  • Diamantis GN, Kim Y, Ofori-Atta Z, Devine L, Antoni MH, Reyes V, Johnson J, Kiefer G, Jiang Y, Zandberg DP, Nilsen M, Tohme S, Geller DA, Steel JL. The interdependence of depressive symptoms and sleep in dyads affected by cancer. Health Psychol. 2025 Apr;44(4):391-400. doi: 10.1037/hea0001449. Epub 2024 Nov 25.

  • Steel JL, George CJ, Terhorst L, Yabes JG, Reyes V, Zandberg DP, Nilsen M, Kiefer G, Johnson J, Marsh C, Bierenbaum J, Tageja N, Krauze M, VanderWeele R, Goel G, Ramineni G, Antoni M, Vodovotz Y, Walker J, Tohme S, Billiar T, Geller DA. Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES): a randomised, parallel, phase 3 trial. Lancet. 2024 Apr 6;403(10434):1351-1361. doi: 10.1016/S0140-6736(24)00015-1. Epub 2024 Mar 12.

  • Steel JL, Amin A, Peyser T, Olejniczak D, Antoni M, Carney M, Tillman E, Hecht CL, Pandya N, Miceli J, Reyes V, Nilsen M, Johnson J, Kiefer G, Pappu B, Zandberg DP, Geller DA. The benefits and consequences of the COVID-19 pandemic for patients diagnosed with cancer and their family caregivers. Psychooncology. 2022 Jun;31(6):1003-1012. doi: 10.1002/pon.5891. Epub 2022 Feb 1.

  • Steel JL, Reyes V, Zandberg DP, Nilsen M, Terhorst L, Richards G, Pappu B, Kiefer G, Johnson J, Antoni M, Vodovotz Y, Spring M, Walker J, Geller DA. The next generation of collaborative care: The design of a novel web-based stepped collaborative care intervention delivered via telemedicine for people diagnosed with cancer. Contemp Clin Trials. 2021 Jun;105:106295. doi: 10.1016/j.cct.2021.106295. Epub 2021 Feb 5.

MeSH Terms

Conditions

NeoplasmsDepressionFatiguePain

Interventions

Therapeutics

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehaviorSigns and SymptomsPathological Conditions, Signs and SymptomsNeurologic Manifestations

Study Officials

  • Jennifer L. Steel, PhD

    UPMC Departemnt of Surgery

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director and Associate Professor

Study Record Dates

First Submitted

October 14, 2016

First Posted

October 20, 2016

Study Start

December 1, 2016

Primary Completion

July 1, 2023

Study Completion

July 1, 2023

Last Updated

December 16, 2024

Record last verified: 2024-12

Data Sharing

IPD Sharing
Will share

De-Identified Data may be shared with investigators who request data from the Primary Investigator

Shared Documents
STUDY PROTOCOL, SAP
Time Frame
Data will be available at the end of the study for up to one year.
Access Criteria
Appropriate investigator credentials (MD, PhD) and request, and for up to one year after study completion

Locations